We have investigated whether stimulation of dopamine-2 receptors is involved in the mechanism of the ocular hypotensive action of timolol by observing the effect of blocking these receptors with metoclopromide prior to the administration of timolol.
antagonistic action.'2 Watanabe and Chiou3 showed that incubation of the rabbit iris root ciliary body preparation with timolol resulted in a decrease in dopamine content when compared with control preparations. Alcondon et al. 4 showed that pretreatment of rabbit eyes with atropine significantly antagonised the ocular hypotensive action of timolol and propranolol.
Mekki et al. "7 showed that stimulation of dopamine-2 receptors can reduce intraocular pressure (TOP) in man. Mekki and Turner7 and Lavin and Andrews' have also shown that the two dopamine receptor blockers, metoclopramide and haloperidol, have no ocular hypotensive action in man, though metoclopramide antagonises the ocular hypotensive action of bromocriptine. 7 We have investigated whether stimulation of dopamine-2 receptors is involved in the mechanism of the ocular hypotensive action of timolol by observing the effect of blocking these receptors with metoclopromide prior to the administration of timolol.
Subjects and methods
Six healthy volunteers, three males and three females, aged 22-35 years participated in this study. None had a history of asthma or wore contact lenses.
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Each volunteer attended on three occasions one week apart at the same time of day. In each session baseline measurements of intraocuLar pressure (IOP) were taken by non-contact tonometry' and followed by one of three treatments: placebo, timolol alone, or metoclopramide followed by timolol. Three IOP measurements were taken at each time point and the mean was recorded. The treatment administration was arranged as follows: an intravenous injection of either metoclopramide 10 mg or matching placebo was given, folowed 15 minutes later by one drop of timolol 0.5% or placebo into the conjunctival sac of the left eye only, resulting in the three combinations. The treatments were given double-blind balanced design based on two Latin squares. IOP was then measured at one and at two hours after instillation of timolol eye drops. The study has been approved by the local Ethics Committee.
The baseline readings were compared by 2-way analysis of variance, and within-subject comparison revealed no statistical difference between the three trial sessions. The areas under the post-treatment response versus time curves for each subject on each treatment were calculated and compared by analysis of variance. The areas under the curves are presented in Table 1 .
Results
A graphical representation of the IOP responses is shown in Fig. 1 These results show that pretreatment with metoclopramide, a selective dopamine-2 receptor antagonist, did not affect the ocular hypotensive action of timolol. We therefore conclude that stimulation of dopamine-2 receptors does not have an important role in the mechanism of action of timolol in lowering IOP. In high concentrations metoclopramide can also block dopamine-1 receptors,"' but even if this occurred in our study it did not affect the ocular hypotensive action of timolol. The dose of metoclopramide used was the same as that which blocked the action of bromocriptine in our earlier study. 7 Although results from animal experiments show that dopaminergic blockade can be associated with an ocular hypotensive action," 12 and that the action of timolol may be related to the dopaminergic system,3 it seems that this is unlikely in man. 
